2025-12-17 - Analysis Report
Okay, here's a breakdown and analysis of Hims & Hers Health Inc. (HIMS) based on the provided data.

**0) Report in English**

**1) Return Rate Comparison**

*   **Ticker:** HIMS
*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company that provides personalized health and wellness solutions.
*   **HIMS Cumulative Return:** 137.97%
*   **VOO (S&P 500) Cumulative Return:** 73.76%
*   **Divergence:** 68.3 (Relative Divergence: 37.9)

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) with a substantial cumulative return difference of 68.3%. The relative divergence of 37.9 suggests this outperformance is not at its peak historically, leaving room for potential further gains (or corrections).

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta  | Cap(B) |
|------------|--------|-------|---------|-------|--------|
| 2019-2021  | -42.0% | 74.4% | -81.0% | 0.0   | 1.5    |
| 2020-2022  | -19.0% | 78.6% | -18.0% | -0.0  | 1.4    |
| 2021-2023  | -65.0% | 78.6% | -67.0% | -0.1 | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0% | -0.0  | 5.4    |
| 2023-2025  | 149.0% | 80.8% | 82.0% | 0.1 | 8.5    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Volatile, ranging from significant losses to impressive gains. The last two periods show strong positive growth.
*   **MDD (Maximum Drawdown):**  High, indicating substantial risk and price volatility.
*   **Alpha:** Reflects the excess return compared to the benchmark, and similarly volatile but strongly positive in the last two periods. A negative alpha indicates underperformance relative to the benchmark.
*   **Beta:** Generally close to zero, suggesting the stock's price movements are not strongly correlated with the overall market (S&P 500). The Beta of 0.1 in the 2023-2025 period suggests a slightly positive correlation.
*   **Cap(B):**  Market capitalization has grown significantly, indicating increasing investor interest and company growth.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 36.86
*   **Previous Close:** 36.25
*   **Change:** 1.68%
*   **5-day SMA:** 37.194
*   **20-day SMA:** 37.3755
*   **60-day SMA:** 45.5073

**Analysis:**  The current price is slightly below the 5-day and 20-day SMAs, and significantly below the 60-day SMA.  This suggests a recent downward trend, but the positive change from the previous close could indicate a possible short-term rebound.

**3) Index Indicators**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 49.23 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.701 (Positive - indicates upward momentum)
*   **Hybrid Signal:** Buy 100% of cash (27 shares - Very Safe - MRI:0.90). Monthly invest 1.3% of total investment ($1,000.00)
*   **Recent Relative Divergence Change (20 days):** 1.1 (+) - Short-term increase (단기상승)
*   **Expected Return:** 24.2% (Long-term excess return compared to S&P 500)

**Analysis:**  The MRI suggests a medium level of investment risk. The RSI is neutral, the PPO indicates positive momentum, and the hybrid signal recommends a full investment. The recent increase in relative divergence aligns with the short-term increase, and a promising 24.2% expected return.

**4) Recent News & Significant Events**

*   **[2025-12-16] Hims & Hers Health (HIMS): Taking Stock of Valuation After a Sharp 90‑Day Pullback:** Suggests a recent price decline that may warrant revisiting valuation.
*   **[2025-11-17] Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization:** A share repurchase program can boost stock price by reducing the number of outstanding shares.
*   **[2025-12-16] Hims & Hers Scales Technology-Driven Care as Profitability Evolves:** Indicates a focus on efficiency and profitability improvements.
*   **[2025-12-10] $HIMS stock is down 5% today. Here's what we see in our data:** Acknowledges a recent price drop, suggesting investor concern.
*   **[2025-11-26] Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?:**  Addresses a recent decline and explores the potential for a buying opportunity.
*   **[2025-12-02] Hims is crashing, but its secret biotech bet is exploding:**  Highlights a potential positive catalyst within the company's biotech ventures.

**Analysis:** Recent news paints a mixed picture. There are concerns about a recent price pullback, but also positive developments like the share repurchase program and the growth in biotech.

**4-2) Analyst Opinions**

*   **Consensus:** Hold (Mean: 2.93)
*   **Target Price (avg/high/low):** 44.67 / 85.00 / 25.00
*   **Recent Rating Changes:** (No specific changes provided)

**Analysis:**  Analysts, on average, have a "Hold" rating, suggesting a neutral outlook. The average target price of $44.67 implies a potential upside from the current price, but the wide range between high and low targets reflects uncertainty.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-03 | 0.07 | 0.60 B$   |
| 2025-08-04 | 0.19 | 0.54 B$   |
| 2025-05-05 | 0.22 | 0.59 B$   |
| 2024-11-04 | 0.35 | 0.40 B$   |
| 2025-11-03 | 0.35 | 0.40 B$   |

**Analysis:**

*   **EPS (Earnings Per Share):** EPS has decreased from 0.35 to 0.07 from 2024-11-04 to 2025-11-03.
*   **Revenue:** Revenue has increased from 0.40B to 0.60B.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.60B  | 73.80%       |
| 2025-06-30 | $0.54B  | 76.39%       |
| 2025-03-31 | $0.59B  | 73.50%       |
| 2024-12-31 | $0.48B  | 76.81%       |
| 2024-09-30 | $0.40B  | 79.16%       |

**Capital and Profitability:**

| Quarter    | Equity  | ROE   |
|------------|---------|-------|
| 2025-09-30 | $0.58B  | 2.72% |
| 2025-06-30 | $0.56B  | 7.55% |
| 2025-03-31 | $0.55B  | 9.01% |
| 2024-12-31 | $0.48B  | 5.46% |
| 2024-09-30 | $0.44B  | 17.18% |

**Analysis:**

*   **Revenue:** Revenue has been growing steadily.
*   **Profit Margin:** Profit margins are high, indicating pricing power and efficient operations.
*   **Equity:** Equity has been increasing, reflecting a strengthening balance sheet.
*   **ROE (Return on Equity):** ROE has been fluctuating and has decreased from 17.18% to 2.72% from 2024-09-30 to 2025-09-30.

**7) Comprehensive Analysis (Summary)**

Hims & Hers Health (HIMS) presents a mixed picture:

*   **Positives:** Strong historical outperformance compared to the S&P 500. Growing revenue, High profit margins. Share repurchase program.
*   **Negatives:** Recent price pullback and negative EPS growth. High Maximum Drawdown suggests volatile stock. Recent news highlights concerns about valuation. Analysts have a neutral "Hold" rating.

**Conclusion:**

HIMS is a high-growth company with considerable potential, but also significant risk. The recent price pullback, analyst sentiment, and fluctuating ROE warrant caution. Investors should carefully consider their risk tolerance and conduct further due diligence before investing. The long-term expected return of 24.2% is attractive, but comes with substantial uncertainty.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.